AI in Healthcare

The UK and Singapore Built the World's First AI Healthcare Regulatory Corridor — India Should Be Watching

By BHC, Editor in Chief · April 01, 2026 · 5 min read

BHC, Editor in Chief — The UK and Singapore Built the World's First AI Healthcare Regulatory Corridor — India Should Be Watching

Summary

  • The UK MHRA and Singapore HSA have created a Regulatory Innovation Corridor for AI and advanced therapies in healthcare. This is what it means for Indian MedTech companies building for global markets.

On March 25, 2026, the UK's Medicines and Healthcare products Regulatory Agency and Singapore's Health Sciences Authority signed a refreshed Memorandum of Understanding establishing what is effectively the world's first bilateral Regulatory Innovation Corridor for healthcare AI and advanced therapies. This is not a symbolic partnership. It is a working framework that allows two sophisticated regulatory bodies to share work, issue joint advice, and accelerate patient access to AI-driven diagnostics, cell therapies, and gene therapies — without duplicating safety processes or creating conflicting standards.

"Realising the potential of emerging technologies requires regulatory excellence that fosters innovation while ensuring safety and trust."

For Indian MedTech founders building AI-powered clinical tools and planning international market entry, this development has direct and practical implications.

**What the Regulatory Innovation Corridor Does

The MHRA-HSA corridor operates through three primary mechanisms. Work-sharing allows both agencies to divide regulatory assessment tasks for specific products — reducing duplication and accelerating review timelines. Early joint advice allows developers to receive aligned regulatory guidance from both agencies at the beginning of the development process, reducing the risk of late-stage redesign. The newly launched Regulatory Innovation Corridor pilot creates a structured pathway for developers of AI tools and advanced therapies to engage with both regulators simultaneously, with coordinated responses.

Adjunct Professor Dr. Raymond Chua, CEO of Singapore's HSA, describes the partnership as a response to the reality that no single regulatory agency has all the answers to the novel challenges posed by AI and advanced therapies. Collaboration is not optional — it is necessary.

**Singapore's Updated AI in Healthcare Guidelines

Singapore has recently updated its AI in Healthcare Guidelines to version 2.0 — specifically to address Generative AI, which was not covered in earlier versions. The updated guidelines articulate good practices for AI developers, healthcare organisations, and healthcare professionals using AI tools, covering areas including validation, transparency, bias management, and clinical oversight. Singapore's approach — updating guidelines proactively ahead of widespread deployment — reflects a regulatory philosophy that the MHRA is also embracing: shape technology through governance, do not simply react to it.

**Why India Needs to Pay Attention

India's regulatory framework for AI in healthcare remains underdeveloped compared to the UK and Singapore. The Central Drugs Standard Control Organisation, India's primary medical device regulator, has begun developing guidelines for Software as a Medical Device — but a comprehensive, internationally aligned AI-in-healthcare regulatory framework does not yet exist.

For Indian MedTech founders, this creates a specific challenge: as they scale into global markets, they increasingly face regulatory environments — in the UK, Singapore, the EU, and the US — that have developed sophisticated, coordinated standards for AI clinical tools. Indian products built without early consideration of these frameworks face significant re-engineering costs at the point of market entry.

The MHRA's National Commission on the Regulation of AI in Healthcare — to which Singapore's HSA now contributes advisors — is actively shaping the standards that will define global best practice. India's absence from these conversations is a gap that should concern founders, investors, and policymakers alike.

**BHC Perspective

At Bengaluru Health Community, we advise health-tech founders building AI clinical tools to treat international regulatory alignment as a product requirement, not an afterthought. Understanding what the MHRA, HSA, FDA, and EU MDR require from AI diagnostic and decision-support tools — and building toward those standards from day one — is a strategic advantage. The UK-Singapore corridor has just raised the global bar. Indian founders who understand and build to that bar will have a significantly easier path to international market entry.

**Frequently Asked Questions

Q: What is the UK-Singapore Regulatory Innovation Corridor for healthcare AI?
A: It is a bilateral agreement between the UK's MHRA and Singapore's HSA that allows both agencies to share regulatory work, issue joint advice, and create coordinated pathways for developers of AI tools and advanced therapies to access both markets more efficiently.

Q: What are Singapore's updated AI in Healthcare Guidelines?
A: Singapore's AI in Healthcare Guidelines version 2.0 cover Generative AI for the first time, providing good practices for AI developers, healthcare organisations, and clinicians on validation, transparency, bias management, and clinical oversight.

Q: How does this affect Indian MedTech startups?
A: Indian MedTech startups planning global market entry will increasingly need to align with the AI regulatory standards being developed by the MHRA, HSA, and other global bodies. Building products without early consideration of these standards creates costly re-engineering risks at the point of international market entry.